Immune checkpoint inhibitors (ICIs) targeting anti‐programmed cell death protein 1 (PD‐1) or its ligand (PD‐L1) have significantly changed the treatment and management of locally advanced and advanced NSCLC.2, 3, 4. This evidence concerns the gene CD274 and non-small cell lung carcinoma.